AGIO Key Statistics, Chart & Performance
The current stock price of AGIO is 28.54 USD. In the past month the price increased by 4.62%. In the past year, price decreased by -17.08%.
AGIO Latest News, Press Relases and Analysis
AGIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About AGIO
Company Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 486 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Company Info
AGIOS PHARMACEUTICALS INC
88 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jacqualyn A. Fouse
Employees: 486
Phone: 16176498600
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What does AGIOS PHARMACEUTICALS INC do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 486 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
What is the stock price of AGIOS PHARMACEUTICALS INC today?
The current stock price of AGIO is 28.54 USD. The price increased by 3.9% in the last trading session.
What is the dividend status of AGIOS PHARMACEUTICALS INC?
AGIO does not pay a dividend.
What is the ChartMill rating of AGIOS PHARMACEUTICALS INC stock?
AGIO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is AGIOS PHARMACEUTICALS INC worth?
AGIOS PHARMACEUTICALS INC (AGIO) has a market capitalization of 1.66B USD. This makes AGIO a Small Cap stock.
Can you provide the ownership details for AGIO stock?
You can find the ownership structure of AGIOS PHARMACEUTICALS INC (AGIO) on the Ownership tab.
Can you provide the short interest for AGIO stock?
The outstanding short interest for AGIOS PHARMACEUTICALS INC (AGIO) is 10.95% of its float.
AGIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AGIO. When comparing the yearly performance of all stocks, AGIO is a bad performer in the overall market: 87.22% of all stocks are doing better.
AGIO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AGIO. While AGIO has a great health rating, there are worries on its profitability.
AGIO Financial Highlights
Over the last trailing twelve months AGIO reported a non-GAAP Earnings per Share(EPS) of -6.7. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.96% | ||
| ROE | -31.24% | ||
| Debt/Equity | 0 |
AGIO Forecast & Estimates
16 analysts have analysed AGIO and the average price target is 32.77 USD. This implies a price increase of 14.81% is expected in the next year compared to the current price of 28.54.
For the next year, analysts expect an EPS growth of -2.92% and a revenue growth 31.15% for AGIO